Liver Diseases

Main Content

NASH Cirrhosis Study

Study title

Multi-center, randomized trial of Emricasan, an oral caspase inhibitor, in subjects with decompensated non-alcoholic steatohepatitis (NASH) Cirrhosis

  • Principal Investigator:  Dr. Thomas Amankonah

Purpose

This study looks at the effects of an experimental drug in the treatment of people with decompensated cirrhosis due to NASH.

Who can participate

Those eligible to participate in this study include:

  • Adults 18 years and older with decompensated cirrhosis caused by NASH

For more information

  • Bronwyn Briseno, RN
    University of Mississippi Medical Center 
    2500 N. State St. 
    Jackson MS 39216 
    (601) 815-5180
  • IRB Number: 2018-0044